Anzeige
Mehr »
Login
Montag, 13.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Silber: Der unverzichtbare Akteur in Boom-Märkten!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
80 Leser
Artikel bewerten:
(0)

I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process

LAKE FOREST, Ill., May 24, 2012 /PRNewswire/ --Hospira, Inc.(NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today released a snapshot of the positive impact of I.V. clinical integration of infusion pumps and electronic health records (EHRs) in honor of Healthcare Technology Management Week, which recognizes the important work of healthcare technology professionals.

(Photo: http://photos.prnewswire.com/prnh/20120524/CG13208-INFO)

(Logo: http://photos.prnewswire.com/prnh/20040503/HSPLOGO)

"The I.V. clinical integration of infusion pumps with electronic health record systems has been shown to decrease the time it takes for nurses to start a new infusion by at least 27 percent,"[1] said Richard Nevin, vice president, Medication Management Systems, U.S., Hospira. "Using I.V. clinical integration to link a smart infusion pump with EHRs helps deliver the trifecta for hospitals: safety, efficiency and financial benefits."

The following multimedia assets provide additional information about how I.V. clinical integration can enhance patient safety, clinician workflow and cost prevention efforts:

  • Why I.V. Clinical Integration of Infusion Pumps is So Smart: This infographic illustrates the functionality and benefits of I.V. clinical integration with Hospira MedNet' safety software, including visuals that reflect the number of steps that can be removed from the medication delivery process.
  • Symbiq' Infusion Pump Overview Video: A quick look at Hospira's newly enhanced Symbiq device -- recently given the first general infusion pump clearance from the U.S. Food and Drug Administration (FDA) under the new 510(k) guidelines -- and the role it plays in I.V. clinical integration.
  • IVclinicalintegration.com: An online hub of visual resources, case studies and news about I.V. clinical integration.

Using I.V. clinical integration to integrate medication management technologies with EHRs enables seamless, near real-time sharing of patient and infusion information between the hospital's clinical information systems, medication pumps and other devices.Intravenous or I.V. medication administration is crucial to the health of patients, as 90 percent of hospital patients receive an infusion as part of their treatments, and 56 percent of all medication errors are associated with I.V. medications.[2],[3] Improving the process through clinical integration can help clinicians positively impact their patients' overall health and safety.

About Hospira

Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness' by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 15,000 employees. Learn more at www.hospira.com.


[1] WellSpan Health. "WellSpan's collaborative efforts lead to Way-Paver," June 10, 2011, http://content.wellspan.org/breakingnews/default.aspx?pageID=11052, Accessed May 17, 2012.

[2] Hanchett, M. Visualizing the IV fluid path as an emerging concept in infection control. Infection Control Today. February 2004.

[3] Ross LM, Wallace J, Paton JY. Medication errors in a pediatric teaching hospital in the UK: five years operational experience. Arch Dis Child. 2000; 83(6);492-497

SOURCE Hospira, Inc.

Lithium vs. Palladium - Ist das die Chance des Jahrzehnts?
Sichern Sie sich den kostenlosen PDF-Report! So können Sie vom Boom der Rohstoffe profitieren.
Hier klicken
© 2012 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.